Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/11/2026, 12:00:00 AM
Takeda's announcement on June 11, 2026, that its TYK2 inhibitor zasocitinib was superior to Sotyktu in a Phase 3 trial, indicating future competition, is expected; 5% price impact estimated due to competitive threat.
Korean Translation
2026년 6월 11일 타케다의 자소시티닙 임상 3상 우월성 발표가 예정됨; 경쟁 위협에 따른 5% 가격 영향이 예상됨.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target is scheduled to report its Q2 2026 financial results on August 19, 2026, with analysts forecasting EPS around $2.21-$2.25. Medium importance is assigned as upcoming earnings are significant catalysts with expected price movement between 5-10%. This event is scheduled.
8/19/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
Second quarter 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release on August 6, 2026, with an estimated ~1% price impact, scheduled.
8/6/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife is scheduled to release its Q2 2026 financial results after the market closes on August 5, 2026; due to typical earnings volatility, a price impact of at least 5% is expected.
8/5/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release scheduled, with analysts forecasting EPS of approximately $1.66. As this is a significant quarterly update, a medium impact is forecasted.
8/3/2026, 12:00:00 AM
Exxon Mobil Corp (XOM) · Earnings Release
Second-quarter 2026 earnings release scheduled for July 31, 2026. Low importance is based on the expected market reaction to a standard earnings release. Analysts forecast earnings per share of approximately $3.76 estimated.
7/31/2026, 12:00:00 AM